Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Trial details
- Registry ID
- NCT06848348
- Drugs studied
- Halneuron, Halneuron (Open Label Extension)
TrialRedline tracks 1 clinical trial sponsored by Dogwood Therapeutics Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic PainNCT06848348 | Halneuron, Halneuron (Open Label Extension) | Active not recruiting | 2026-12Estimated |
Names as written in the registry records.
NCT06848348 · Dogwood Therapeutics Inc.
Before: Jul 2026. After: Dec 2026.
Before: Recruiting. After: Active not recruiting.
NCT06848348 · Dogwood Therapeutics Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To explore the efficacy of Halneuron in the treatment of patients with Chemotherapy-Induced Neuropathic Pain Measure: To explore the Safety of Halneuron in the treatment of patients with Chemotherapy-Induced Neuropathic Pain. After: Measure: NRS Pain Measure: Safety Assessments.
Before: 200 participants (planned). After: 240 participants (planned).